Posts

Highlights from landmark November studies in thoracic oncology.

Highlights from landmark October studies in thoracic oncology.

The most practice-changing, promising, and watchlist data — distilled into 3 bullets each.

ESMO 2025 brings a strong thoracic-oncology program, spanning peri-operative immunotherapy, next-generation ADCs, and long-term targeted-therapy follow-up. Below are ten key abstracts to keep on your radar.

September 2025 brought big shifts in thoracic oncology — from DLL3 bispecifics in ES-SCLC to new data reinforcing PACIFIC in stage III NSCLC, plus real-world survivorship insights. Here’s the key data you need this month.